Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.
BörsenkürzelPCRX
Name des UnternehmensPacira Biosciences Inc
IPO-datumFeb 03, 2011
CEOMr. Frank D. Lee
Anzahl der mitarbeiter790
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 03
Addresse2000 Sierra Point Parkway
StadtBRISBANE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94005
Telefon16502428052
Websitehttps://www.pacira.com/
BörsenkürzelPCRX
IPO-datumFeb 03, 2011
CEOMr. Frank D. Lee
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten